Literature DB >> 33569622

Short diameter may be a useful simple indicator of the tumor response in skull base meningiomas after conventionally fractionated stereotactic radiotherapy.

Keiichi Takehana1, Daisuke Nakamura1,2, Alshaymaa Abdelghaffar1,3, Megumi Uto1, Tomohiro Katagiri1, Yoshiki Arakawa4, Yohei Mineharu4, Susumu Miyamoto4, Takashi Mizowaki5.   

Abstract

OBJECTIVES: The purpose of this study was to assess the radiological change patterns in skull base meningiomas after conventionally fractionated stereotactic radiotherapy (CFSRT) to determine a simple and valid method to assess the tumor response.
MATERIALS AND METHODS: Forty-one patients with a benign skull base meningioma treated by CFSRT from March 2007 to August 2015 were retrospectively evaluated. We measured tumor volume (TV), long-axis diameter (LD), and short-axis diameter (SD) on both pre-treatment images and follow-up images of 1, 3, and 5 years after CFSRT, respectively. The paired t test was used to detect differences in the LD and SD change rates. Spearman's correlation coefficients were calculated to evaluate relationships between the TV and the diameters changes.
RESULTS: The number of available follow-up MRIs that was performed at 1, 3, and 5 years after the CFSRT was 41 (100%), 34 (83%), and 23 (56%), respectively. The change rates of SD were significantly higher than those of LD at every time point and more strongly correlated with the change rates of tumor volume at 3 and 5 years after CFSRT.
CONCLUSIONS: SD may be useful as a simple indicator of the tumor response for skull base meningioma after CFSRT. KEY POINTS: • The change rate in short-axis diameter is a useful and simple indicator of the response of skull base meningioma to conventionally fractionated stereotactic radiotherapy. • Conventionally fractionated stereotactic radiotherapy for skull base meningioma achieved excellent 5-year local control.
© 2021. The Author(s).

Entities:  

Keywords:  Follow-up studies; Meningioma; Response Evaluation Criteria in Solid Tumors; Skull base; Stereotactic radiation therapy

Mesh:

Year:  2021        PMID: 33569622     DOI: 10.1007/s00330-021-07707-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  17 in total

1.  Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy.

Authors:  Emily Tanzler; Christopher G Morris; Jessica M Kirwan; Robert J Amdur; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-06       Impact factor: 7.038

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Hypofractionated stereotactic radiation therapy in skull base meningiomas.

Authors:  Pierina Navarria; Federico Pessina; Luca Cozzi; Elena Clerici; Elisa Villa; Anna Maria Ascolese; Fiorenza De Rose; Tiziana Comito; Ciro Franzese; Giuseppe D'Agostino; Francesca Lobefalo; Antonella Fogliata; Giacomo Reggiori; Maurizio Fornari; Stefano Tomatis; Lorenzo Bello; Marta Scorsetti
Journal:  J Neurooncol       Date:  2015-06-04       Impact factor: 4.130

4.  Long-Term Results of Stereotactic Radiosurgery for Skull Base Meningiomas.

Authors:  Or Cohen-Inbar; Cheng-Chia Lee; David Schlesinger; Zhiyuan Xu; Jason P Sheehan
Journal:  Neurosurgery       Date:  2016-07       Impact factor: 4.654

5.  Significance of tumor volume related to peritumoral edema in intracranial meningioma treated with extreme hypofractionated stereotactic radiation therapy in three to five fractions.

Authors:  Masahiro Morimoto; Yasuo Yoshioka; Hiroya Shiomi; Fumiaki Isohashi; Koji Konishi; Tadayuki Kotsuma; Shoichi Fukuda; Naoki Kagawa; Manabu Kinoshita; Naoya Hashimoto; Toshiki Yoshimine; Masahiko Koizumi
Journal:  Jpn J Clin Oncol       Date:  2011-03-16       Impact factor: 3.019

Review 6.  Response assessment in neuro-oncology.

Authors:  Eudocia C Quant; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

7.  Intensity-modulated radiation therapy (IMRT) for meningioma.

Authors:  Nathan W Uy; Shiao Y Woo; Bin S Teh; Wei Yuan Mai; L Steven Carpenter; Joseph K Chiu; Hsin H Lu; Phillip Gildenberg; Todd Trask; Walter H Grant; E Brian Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

Review 8.  Meningioma.

Authors:  Christine Marosi; Marco Hassler; Karl Roessler; Michele Reni; Milena Sant; Elena Mazza; Charles Vecht
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-14       Impact factor: 6.312

Review 9.  Meningiomas.

Authors:  Ian R Whittle; Colin Smith; Parthiban Navoo; Donald Collie
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

10.  Stereotactic radiotherapy for treatment of cavernous sinus meningiomas.

Authors:  Michael T Selch; Eugene Ahn; Ashkan Laskari; Steve P Lee; Nhzde Agazaryan; Timothy D Solberg; Cynthia Cabatan-Awang; Leonardo Frighetto; Antonio A F Desalles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.